Factor IXa for the treatment of bleeding disorders
US7425539B2 · kind B2 · utility
34Cited by
14References
4Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Feb 28, 2005 |
| Grant date | Sep 16, 2008 |
| Priority date | — |
| Expiry date | Feb 28, 2025 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P7/04
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention provides a method of treating bleeding disorders in a subject by administration of a preparation enriched for Factor IXa. The Factor IXa can be produced by proteolytically activating recombinantly-produced Factor IX. The invention also provides an improved method for producing Factor IXa from a plasma fraction, which method results in a Factor IXa product containing little or no prekallikrein activity, thus reducing the incidence of undesired side effects in a subject.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.